BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

...testing to treat multiple myeloma and systemic sclerosis. Targets BAG3 (CAIR-1) - BCL2-associated athanogene 3 Perlecan...
BioCentury | Sep 12, 2019
Distillery Therapeutics

Perlecan identified as new tumor stroma target

...DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Depleting perlecan, a protein deposited in the tumor stroma by...
...cancer associated fibroblasts (CAFs), could help treat metastatic pancreatic cancer. An Australian team showed that perlecan...
..."Australian Researchers Uncover Perlecan's Role in the Tumor Stroma" ). TARGET/MARKER/PATHWAY: Heparan sulfate proteoglycan 2 (Perlecan...
BioCentury | Sep 12, 2019
Translation in Brief

Australian researchers uncover perlecan’s role in the tumor stroma

...An Australian team has uncovered perlecan as the latest in a growing list of new therapeutic...
...promote tumor cell invasion. They do so, at least in part, by increasing deposition of perlecan...
...tumor cells. CAFs conditioned with highly metastatic cancers had higher perlecan secretion, and knocking out perlecan...
BioCentury | Jul 21, 2011
Distillery Therapeutics

Indication: Neurology

...Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Perlecan Rodent studies suggest that perlecan...
...DV) could help treat stroke. In rat and mouse models of stroke, intraperitoneal administration of perlecan...
...middle cerebral artery occlusion restored motor functions to prestroke levels compared with administration of heat-inactivated perlecan...
BioCentury | May 21, 2009
Distillery Therapeutics

Indication: Endocrine disease

...studies of the galegine analogs. DRL-16536, an AMPK modulator from Dr. Reddy's Laboratories Ltd. and Perlecan Pharma Pvt. Ltd....
BioCentury | Feb 25, 2008
Strategy

Offloading R&D in India

...with private equity investors ICICI Venture and Citigroup Venture Capital International Mauritius Ltd. to form Perlecan...
...each to put in $22.5 million. Perlecan has received a first tranche of $26 million. Perlecan...
...has the right of refusal on Dr Reddy's future pipeline opportunities. Since the formation of Perlecan...
BioCentury | Oct 3, 2005
Company News

Dr. Reddy's endocrine, cardiovascular news

...RDY spun out Perlecan Pharma Private Ltd. to develop therapeutics for endocrine and cardiovascular diseases. The...
...predominantly PPAR alpha agonist that has completed Phase I testing for dyslipidemia; RUS 3108, a perlecan...
...Perlecan in India, China and Russia and other countries in the Commonwealth of Independent States. Perlecan...
BioCentury | Sep 29, 2005
Company News

Dr. Reddy's spins out Perlecan

...RDY spun out Perlecan to develop therapeutics for endocrine and cardiovascular diseases. The newco takes with...
...PPAR alpha agonist that has completed Phase I testing for dyslipidemia; RUS 3108 , a perlecan...
...Perlecan in India, China and Russia and other countries in the Commonwealth of Independent States. Perlecan...
BioCentury | Feb 14, 2005
Clinical News

RUS 3108: Started Phase I

...Reddy's Laboratories Ltd. (RDY), Hyderabad, India Product: RUS 3108 Business: Cardiovascular Molecular target: Perlecan Description: Perlecan...
Items per page:
1 - 9 of 9
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

...testing to treat multiple myeloma and systemic sclerosis. Targets BAG3 (CAIR-1) - BCL2-associated athanogene 3 Perlecan...
BioCentury | Sep 12, 2019
Distillery Therapeutics

Perlecan identified as new tumor stroma target

...DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Depleting perlecan, a protein deposited in the tumor stroma by...
...cancer associated fibroblasts (CAFs), could help treat metastatic pancreatic cancer. An Australian team showed that perlecan...
..."Australian Researchers Uncover Perlecan's Role in the Tumor Stroma" ). TARGET/MARKER/PATHWAY: Heparan sulfate proteoglycan 2 (Perlecan...
BioCentury | Sep 12, 2019
Translation in Brief

Australian researchers uncover perlecan’s role in the tumor stroma

...An Australian team has uncovered perlecan as the latest in a growing list of new therapeutic...
...promote tumor cell invasion. They do so, at least in part, by increasing deposition of perlecan...
...tumor cells. CAFs conditioned with highly metastatic cancers had higher perlecan secretion, and knocking out perlecan...
BioCentury | Jul 21, 2011
Distillery Therapeutics

Indication: Neurology

...Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Perlecan Rodent studies suggest that perlecan...
...DV) could help treat stroke. In rat and mouse models of stroke, intraperitoneal administration of perlecan...
...middle cerebral artery occlusion restored motor functions to prestroke levels compared with administration of heat-inactivated perlecan...
BioCentury | May 21, 2009
Distillery Therapeutics

Indication: Endocrine disease

...studies of the galegine analogs. DRL-16536, an AMPK modulator from Dr. Reddy's Laboratories Ltd. and Perlecan Pharma Pvt. Ltd....
BioCentury | Feb 25, 2008
Strategy

Offloading R&D in India

...with private equity investors ICICI Venture and Citigroup Venture Capital International Mauritius Ltd. to form Perlecan...
...each to put in $22.5 million. Perlecan has received a first tranche of $26 million. Perlecan...
...has the right of refusal on Dr Reddy's future pipeline opportunities. Since the formation of Perlecan...
BioCentury | Oct 3, 2005
Company News

Dr. Reddy's endocrine, cardiovascular news

...RDY spun out Perlecan Pharma Private Ltd. to develop therapeutics for endocrine and cardiovascular diseases. The...
...predominantly PPAR alpha agonist that has completed Phase I testing for dyslipidemia; RUS 3108, a perlecan...
...Perlecan in India, China and Russia and other countries in the Commonwealth of Independent States. Perlecan...
BioCentury | Sep 29, 2005
Company News

Dr. Reddy's spins out Perlecan

...RDY spun out Perlecan to develop therapeutics for endocrine and cardiovascular diseases. The newco takes with...
...PPAR alpha agonist that has completed Phase I testing for dyslipidemia; RUS 3108 , a perlecan...
...Perlecan in India, China and Russia and other countries in the Commonwealth of Independent States. Perlecan...
BioCentury | Feb 14, 2005
Clinical News

RUS 3108: Started Phase I

...Reddy's Laboratories Ltd. (RDY), Hyderabad, India Product: RUS 3108 Business: Cardiovascular Molecular target: Perlecan Description: Perlecan...
Items per page:
1 - 9 of 9